MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hemostemix Inc (OP:HMTXF)

0.0625 -0.0004 (-0.64%)
Streaming Delayed Price Updated: 11:11 AM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 443
Open 0.0625
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.0629
Today's Range 0.0625 - 0.0625
52wk Range 0.0500 - 0.2850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01
Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"),... 
Via Newsfile
News headline image
Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv)
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's... 
Via Newsfile

Performance

YTD
-21.9%
-21.9%
1 Month
-0.6%
-0.6%
3 Month
-16.4%
-16.4%
6 Month
-31.4%
-31.4%
1 Year
+16.0%
+16.0%

More News

Read More
News headline image
Hemostemix Grants Stock Options
Via Newsfile
News headline image
Hemostemix Inc. Announces FDA Pre-IND Meeting and NBPP of $960,000
Via Newsfile
News headline image
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum Agenda Announced for September 18th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Hemostemix Announces the Appointment of Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI to Its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Terry Hébert, PhD, to Its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Nadia Giannetti, MD, to its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces the Appointment of Dr. Johannes Grillari to its Scientific Advisory Board
Via Newsfile
Topics Intellectual Property
News headline image
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board
Via Newsfile
News headline image
Hemostemix Announces Its Presentation to the Emerging Growth Conference
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Announces the Appointment of Thomas Abraham, CA as President, PreCerv Inc.
Via Newsfile
News headline image
Hemostemix Announces Closing of $2,750,000
Via IssueWire
Topics Intellectual Property
News headline image
Hemostemix Inc. Announces Intellectual Property Due Diligence and Data Audit Completed
Via IssueWire
Topics Intellectual Property Lawsuit
News headline image
Your Fountain of Youth Trademarked by Hemostemix Inc.
Via IssueWire
Topics Intellectual Property
News headline image
Hemostemix Announces Closing of UNIT Private Placement
Via IssueWire
News headline image
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday ↗
Via Benzinga
News headline image
Hemostemix Announces the First of a Series of 2021 Video Interviews with ACP-01 Recipients: What the Successful Compassionate Treatment of Ischemic Cardiomyopathy Looks Like After 13 Years
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Provides Update of Phase II Clinical Trial, 9th Circuit Court Decision Including Cost Award and its Annual General Meeting Results
Via Newsfile
Topics Economy Intellectual Property
News headline image
Peter Lacey Increases His Investment in Hemostemix Inc.
Via Newsfile
Topics Intellectual Property
News headline image
Hemostemix Announces the Closing of a $2,500,000 Convertible Debenture
Via Newsfile
Topics Economy Intellectual Property
News headline image
Hemostemix Announces Completion of Phase II Clinical Trial Subject Follow Up and HMTXF Up-list
Via Newsfile
Topics Economy Intellectual Property

Frequently Asked Questions

Is Hemostemix Inc publicly traded?
Yes, Hemostemix Inc is publicly traded.
What exchange does Hemostemix Inc trade on?
Hemostemix Inc trades on the OTC Traded
What is the ticker symbol for Hemostemix Inc?
The ticker symbol for Hemostemix Inc is HMTXF on the OTC Traded
What is the current price of Hemostemix Inc?
The current price of Hemostemix Inc is 0.0625
When was Hemostemix Inc last traded?
The last trade of Hemostemix Inc was at 12/26/25 11:11 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story